title: Prophylactic efficacy of persistent anthelmintics against challenge with drug-resistant and susceptible Ostertagia circumcincta.
abstract: Three groups of newly-weaned Romney lambs were given either a standard oral dose of albendazole, a controlled-release capsule containing albendazole, or a standard oral dose of moxidectin. At 10, 20, 30 and 40 days after treatment, sub-groups of lambs were given 10,000 infective-stage larvae of either a drug-resistant or a drug-susceptible strain of Ostertagia circumcincta. The recommended oral dose of albendazole removed 32 per cent of the resistant strain and over 99.9 per cent of the susceptible O. circumcincta. The recommended oral dose of moxidectin removed 91 per cent of the resistant strain and over 99.9 per cent of the susceptible parasites. None of the lambs treated with controlled-release capsules was challenged at 20 or 30 days after treatment. Twenty-one days after challenge, samples of faeces were taken to determine the presence of nematode eggs and cultured to establish the proportion of eggs developing to infective-stage larvae (L3). Abomasa were recovered after slaughter and worm burdens determined. In the lambs given controlled-release capsules only the resistant parasites were able to establish, and there were significantly fewer than in the lambs treated orally with albendazole. The proportion of the eggs from resistant parasites which developed to L3 was not reduced by the presence of the capsules. Oral moxidectin provided no protection against the establishment of the resistant strain and viable L3 were recovered after challenge with resistant parasites 10 days after treatment; however, the establishment of susceptible O. circumcincta was reduced by more than 99 per cent. The establishment of the susceptible parasites in the lambs treated with moxidectin increased with time and was not significantly lower than in the other groups by 30 days after treatment.
authors.affiliation: AgResearch, Grasslands, Palmerston North, New Zealand.
authors.forename: I A
authors.initials: IA
authors.lastname: Sutherland
authors.forename: D M
authors.initials: DM
authors.lastname: Leathwick
authors.forename: A E
authors.initials: AE
authors.lastname: Brown
authors.forename: C M
authors.initials: CM
authors.lastname: Miller
mesh_terms: D000284:Administration, Oral; D015766:Albendazole / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000494:pharmacology*; D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; D004351:Drug Resistance; D018942:Macrolides / Q000008:administration & dosage / Q000494:pharmacology; D010028:Ostertagia / Q000187:drug effects* / Q000469:parasitology; D010029:Ostertagiasis / Q000188:drug therapy* / Q000517:prevention & control; D012756:Sheep; D012757:Sheep Diseases / Q000188:drug therapy* / Q000469:parasitology
chemical_list: D000871:Anthelmintics; D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; D018942:Macrolides; D015766:Albendazole; C027837:moxidectin